List of publications – Thymidine Kinase (TK1)

List of Publications – Thymidine Kinase 1 (TK1)

The body of scientific evidence for thymidine kinase 1 (TK1) currently includes over 50 peer-reviewed studies, and continues to grow as the research expands.

The publication list below contains the 34 most recently listed studies, and is continuously updated. By clicking on each individual study title, you will be linked to the corresponding abstract in PubMed.

For a complete list of all publications currently available on Thymidine Kinase 1, please download the pdf file listed at the bottom of this page.

Jagarlamudi KK, Wang L, Eriksson S
Doxorubicin effects on leukemia and breast cancer cells in culture on the TK1 protein levels using AroCell TK 210 ELISA: a tool for drug development.
Nucleosides Nucleotides Nucleic Acids,
Published online 06 December 2018.

Tribukait B, Jagarlamudi KK Bergh K, Hatschek T
Quantitation of cell loss in breast cancer during neoadjuvent treatment (NACT) assessed by serum thymidine kinase protein concentration (sTK1).
Annals of Oncology, Vol 28: Issue Suppl 10, 1 November 2017, mdx655.023, Published 22 November 2017.

Kiran Kumar J, Wang L, Eriksson S.
Doxorubicin effects on TK1 protein levels in leukemia and breast cancer cell cultures measured using AroCell TK 210 ELISA
Purine and Pyrimidine Society, Gdansk, Sept 20-24, 2017

Kiran Kumar J, Eriksson S, Moca Z, Kumer K, Osredkar J, Teja F, Heibic G, Smrkolj T.
The AroCell TK 210 ELISA may complement Pro PSA and the Prostate Health Index in differentiating pre cancerous and cancerous conditions in prostate cancer.
Abstract 715, Proceedings AACR Annual Mtg 2017, AACR Journals/77/13 Supplement/715 short.

Kiran Kumar J, Aronsson AA, Pilko G, Zupan M, Kumer K, Fabjan T, Osredkar J, Eriksson S.
A Clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease
Tumor Biology. Published online 14 April 2016

Eriksson S, Kiran Kumar J, Nilsson O, Venge P, Aronsson AC.
The TK 210 ELISA is a robust method to determine thymidine kinase 1 protein levels in serum samples.
Tumor Biol. 2015 36 (Suppl 1) S57, 2015.

Jagarlamudi KK, Tribukait B , Zupan M, K. Kumer K, Fabjan T,  Osredkar J, Smrkoli T, Eriksson S.
The TK 210 ELISA can measure increased TK1 protein levels in sera from prostate cancer patients with different Gleason scores.
Tumor Biol.2015 36 (Suppl 1) S34-S35, 2015.

Zhou J, He E, Skog S.
The proliferation marker thymidine kinase 1 in clinical use.
Mol Clin Oncol 2013 Jan;1(1):18-28. Epub 2012 Sep 4.

Hanan S, Jagarlamudi KK, Liya W, Ellen H, Staffan E.
Quaternary structures of recombinant, cellular, and serum forms of thymidine kinase 1 from dogs and humans.
BMC Biochem 2012 Jun 28;13:12. doi: 10.1186/1471-2091-13-12.

Chen YL, Eriksson S, Chang ZF.
The regulation and functional contribution of thymidine kinase 1 in repair of DNA damage.
J Biol Chem. 2010 Aug 27;285(35):27327-35. doi: 10.1074/jbc.M110.137042. Epub 2010 Jun 16.

He E, X XH, Guan H, Chen Y, Chen ZH, Pan ZL, Tang LL Hu GZ, Li Y, Zhang M, Zhou J, Eriksson S, Fornander T, Skog S.
Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin’s lymphoma.
Nucleosides Nucleotides Nucleic Acids. 2010, 29 (4-6): p. 352-8.

Li Z, Wang Y, Ma J, He S, Zhou J, He E, Skog S.
Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma.
Anticancer Res. 2010, 30(4): p. 1295-9.

Li Z, Wang Y, He J, Ma J, Zhao L, Chen H, Li N Zhou J, He H, Skog S.
Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas.
Eur J Cancer Prev. 2010, 19(4): p. 313-8.

Chen Y, Ying M, Chen Y, Hu M, Lin Y, Chen D, Li X, Zhang M, Yun X, Zhou J, He E, Skog S.
Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.
Int J Clin Oncol. 2010 Aug;15(4):359-68. doi: 10.1007/s10147-010-0067-4. Epub 2010 Apr 1.

Pan ZL, Ji XY, Shi YM, Zhou J, He E, Skog S.
Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients.
J Cancer Res Clin Oncol. 2010 Aug; 136(8):1193-9. doi: 10.1007/s00432-010-0769-z. Epub 2010 Feb 7.

Luo P, Wang N, He E, Eriksson S, Zhou J, Hu G, Zhong J. Skog S.
The proliferation marker thymidine kinase 1 level is high in normal kidney tubule cells compared to other normal and malignant renal cells.
Pathol Oncol Res. 2010 Jun;16(2):277-83. doi: 10.1007/s12253-009-9222-5. Epub 2009 Dec 3.

Barwick T, Bencherif B, Mountz JM, Avril N.
Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation.
Nucl Med Commun. 2009 Dec;30(12):908-17. doi: 10.1097/MNM.0b013e32832ee93b20.

Brockenbrough JS, Morihara JK, Howes SE, Stern JE, Rasey JS, Wiens LW, Feng Q, Vesselle H.
Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.
J Histochem Cytochem. 2009 Nov;57(11):1087-97. doi: 10.1369/jhc.2009.952804. Epub 2009 Aug 3.

Xu W, Cao X, Miao KR, Qiao C, Wu YJ, Liu Q, Fan L, Li JY.
Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors.
Int J Hematol. 2009 Sep;90(2):205-11. doi: 10.1007/s12185-009-0380-8. Epub 2009 Jul 2413.

Carlsson L, Larsson A, Lindman H.
Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer.
Ups J Med Sci. 2009;114(2):116-20. doi: 10.1080/03009730802688835.

Luo P, He E, Eriksson S, Zhou J, Hu G, Zhang J, Skog S..
Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
Eur J Cancer Prev. 2009 Jun;18(3):220-4. doi: 10.1097/CEJ.0b013e328329d817.

Chen Z, Zhou H, Li S, He E, Hu J, Zhou J, Skog S.
Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumours.
Anticancer Res. 2008 Nov-Dec;28(6B):3897-907.

Von Euler HP, Rivera P, Aronson AC, Bengtsson C, Hansson LO, Eriksson SK.
Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity–evaluation of a new, fully automated non-radiometric assay.
Int J Oncol. 2009 Feb;34(2):505-10.

van Waarde A, Elsinga PH.
Proliferation markers for the differential diagnosis of tumor and inflammation.
Curr Pharm Des. 2008;14(31):3326-339.

Direcks WG, Berndsen SC, Proost N, Peters GJ Balzarin J, Spreeuwenberg MD, Lammertsma AA, Moltoff CF.
[18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study.
Br J Cancer. 2008 Aug 5;99(3):481-7. doi: 10.1038/sj.bjc.6604523.

Bading JR, Shields AF.
Imaging of cell proliferation: status and prospects.
J Nucl Med. 2008 Jun;49 Suppl 2:64S-80S. doi: 10.2967/jnumed.107.046391.

Barth RF, et al.
Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors.
Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17493-7. doi: 10.1073/pnas.0809569105. Epub 2008 Nov 3.

Topolcan O, Holubec L Jr.
The role of thymidine kinase in cancer diceases.
Expert Opin. Med Diagn. 2008 Feb;2(2):129-41. doi: 10.1517/17530059.2.2.129.

Votava T, Topolcan O, Holubec L Jr, Cerna Z, Sasek L, Finek J, Kormunda S.
Changes of serum thymidine kinase in children with acute leukemia.
Anticancer Res. 2007 Jul-Aug;27(4A):1925-8.

TK1 Scientific Publication List 2017